NAB’s pot loan is going up in smoke

For the long-suffering shareholders in listed medicinal cannabis player Cann Group, it’s a case of buy high, sell low – assuming the company ever makes it back to the ASX boards.

Once valued at near $530 million off a wave of takeover speculation and in-principle research agreements with universities, Cann’s market capitalisation has sunk back to just $27 million after weathering a series of rolling crises.